Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Sponsor
Damanhour University
Study ID
NCT05911724
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

Key Dates

Start date
Mar 1, 2023
Status verified
Jan 2025
Primary completion
Sep 20, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
180 participants (actual)

Arms

  • Arm: Group I
    60 Healthy Subjects.
  • Arm: Group II
    60 Patients with Stable Angina on empagliflozin 10 mg once daily for 6 months before the beginning of the study.
  • Arm: Group III
    60 Patients with Heart Failure on empagliflozin 10 mg once daily for 6 months before the beginning of the study.

Primary Outcome Measure

All Cause 30 day hosptial admission [ Time Frame: 1 month ]

Related Studies